Isotopic Abundance Ratio Evaluation of the Consciousness Energy Treated Pyridoxine Using LC-MS and GC-MS Spectrometry

Isotopic Abundance Ratio Evaluation of the Consciousness Energy Treated Pyridoxine Using LC-MS and GC-MS Spectrometry

Materials Science

Vitamin B6 (pyridoxine) has an important role in physiologic development. In this study, the influence of the Trivedi Effect®- Consciousness Energy Treatment on the structural properties and the isotopic abundance ratio of pyridoxine were evaluated using LC-MS and GC-MS analytical techniques. The test sample pyridoxine was divided into Control / untreated and the Biofield Energy Treated sample. The treated pyridoxine sample received Biofield Energy Treatment (the Trivedi Effect®) remotely for ~3 minutes by Mr. Mahendra Kumar Trivedi, who was in the USA, while the test samples were in the research laboratory in India. The LC-MS spectra of both the samples at retention time ~2.33 minutes exhibited the mass of the protonated molecular ion peak [M+H] + at m/z 170 in the MS spectrum. The isotopic abundance ratio of PM+1/PM in the treated pyridoxine was significantly increased by 14.44% compared with the control sample. Thus, 13C, 2H, 15N, and 17O contributions from (C8H12NO3) + to m/z 171 in the treated sample were significantly increased compared with the control sample. Similarly, in the GC-MS chromatograms, the peak area of the treated sample was significantly increased by 100.63% compared to the control sample. Similarly, the mass peak intensity of the treated pyridoxine at m/z 153 was increased by 1.1% compared to the control sample. The isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) and peak area in the treated pyridoxine was significantly increased compared to the control sample. The decreased isotopic abundance ratio of the treated pyridoxine may increase the intra-atomic bond strength, increase its physical stability. The increased peak area of the treated pyridoxine might be responsible for the increase in solubility and bioavailability compared to the control sample. The new form of pyridoxine would be better for designing more efficacious nutraceutical formulations for the prevention and treatment of pyridoxine deficiency, anemia, seizures, cardiovascular disease, tuberculosis, Alzheimer’s disease, cancer, anxiety, hypertension, asthma, depression, dysmenorrhea, breast pain, etc.

11-Feb-2021

Juniper Publishers

11-Feb-2021

[no text]

[no text]

[no text]

[no text]

English

Journal Article

[no text]

[no text]